"Among these drugs are steroids for the treatment of inflammation, anticoagulants to prevent blood clots and antibiotics against secondary bacterial infections ... The cost of these drugs exceeds $ 70 million, they will be provided immediately," RIA Novosti quoted the head of the company Albert Burla as saying.
As Burla noted, at the moment, the primary task is related to the treatment of the infected.
At the same time, he said, the vaccine has not yet been registered in India, although the company filed a corresponding application several months ago.
Earlier it was reported that the first cases of the Indian strain of COVID-19 were detected in Morocco and Algeria.